Russian experts have claimed in the results of Phase II of the clinical trial of the locally developed corona vaccine Sputnik V that the vaccine is up to 95% effective against the corona epidemic.
The government-run Gamalia Research Center and the Russian Foreign Investment Fund (RDIF) said the findings were based on preliminary data obtained 42 days after the first dose.
The second control point according to the clinical trial protocol was based on the analysis of data from volunteers receiving the first and second doses of Sputnik V vaccine or placebo.
The company said in a statement that preliminary data from volunteers were obtained 42 days after the first dose, indicating the effectiveness of more than 95% of the vaccines.
The company said the Sputnik V COVID-19 vaccine would cost less than ڈالر 10 and would be available on world markets for a total of 740 rubles.
The vaccine will be provided free of charge to Russian citizens.
After many other countries, Brazil is now ready to acquire the Russian corona vaccine. In this regard, the Brazilian Ministry of Health is going to sign an agreement with Russia regarding the purchase of Sputnik V.
According to Russian media, the Brazilian Ministry of Health is ready to sign an agreement with RDIF (Russian Direct Investment Fund) regarding the possible purchase of the Russian corona vaccine Sputnik V.
According to the Brazilian Ministry of Health, similar agreements will be made with the major US pharmaceutical company Pfizer Johnson Selg Indian Biotech and Moderna.
Last week, Brazilian healthcare officials met with representatives of vaccine companies to discuss the safety and effectiveness of the vaccine. The logistical aspects of its supply were also discussed.